MedTrace Logo

Epidemiological and Pathophysiological Insights Through a Cross-sectional Survey (EPIC)

NCT06840860 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2025-05-02

No results posted yet for this study

Summary

This study aims to better understand how mpox is spreading in the DRC, how it affects different groups of people, and how well vaccines protect against it. The study is designed as a cross-sectional survey, meaning researchers will collect and analyze data from patients diagnosed with mpox at a single point in time. It will also use a case-control approach, comparing people who test positive for the virus to those who test negative, to identify risk factors and evaluate the effectiveness of the vaccine.

Conditions

  • Monkeypox (Mpox)

Sponsors & Collaborators

  • University of Manitoba

    collaborator OTHER

  • Catholic University of Bukavu, Democratic Republic of Congo

    collaborator UNKNOWN

  • University of Bern

    collaborator OTHER

  • Alliance for International Medical Action

    collaborator OTHER

  • Institut de Recherche pour le Developpement

    collaborator OTHER_GOV

  • Institut National de Recherche Biomédicale. Kinshasa, République Démocratique du Congo

    collaborator OTHER

  • European and Developing Countries Clinical Trials Partnership (EDCTP)

    collaborator OTHER_GOV

  • University of California, Los Angeles

    collaborator OTHER

  • Institute of Tropical Medicine, Belgium

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-28
Primary Completion
2027-02-28
Completion
2027-02-28

Countries

  • Democratic Republic of the Congo

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06840860 on ClinicalTrials.gov